SOS-AMI Multi-Center, Double-Blind, Randomized , Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Self-Administered Subcutaneous Selatogrel for Prevention of All-Cause D

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Deepak Acharya
Sponsor
Idorsia Pharmaceutical (Switzerland)
Unit
Sarver Heart Center